Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sihuan Pharmaceutical Holdings Group's quarterly Ending Cash Position
declined
from Dec. 2024 (HK$3,761 Mil) to Jun. 2025 (HK$3,560 Mil) but then
increased
from Jun. 2025 (HK$3,560 Mil) to Dec. 2025 (HK$3,933 Mil).
Sihuan Pharmaceutical Holdings Group's annual Ending Cash Position
declined
from Dec. 2023 (HK$4,133 Mil) to Dec. 2024 (HK$3,761 Mil) but then
increased
from Dec. 2024 (HK$3,761 Mil) to Dec. 2025 (HK$3,933 Mil).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sihuan Pharmaceutical Holdings Group Ending Cash Position Chart
Sihuan Pharmaceutical Holdings Group Ending Cash Position Calculation
Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.
What does a Ending Cash Position of HK$3,933 Mil mean?
Sihuan Pharmaceutical Holdings Group (HKSE:00460) has a Ending Cash Position of HK$3,933 Mil as of Dec. 2025. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Sihuan Pharmaceutical Holdings Group and its competitors.
Is Sihuan Pharmaceutical Holdings Group's Ending Cash Position too high?
Sihuan Pharmaceutical Holdings Group's current Ending Cash Position is HK$3,933 Mil. Overall, Sihuan Pharmaceutical Holdings Group has a GF Score™ of 79/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sihuan Pharmaceutical Holdings Group's Ending Cash Position compare to ZTS?
Sihuan Pharmaceutical Holdings Group's Ending Cash Position of HK$3,933 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Drug Manufacturers company?
A good Ending Cash Position depends on the Drug Manufacturers industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Sihuan Pharmaceutical Holdings Group and its competitors. Sihuan Pharmaceutical Holdings Group's current Ending Cash Position is HK$3,933 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sihuan Pharmaceutical Holdings Group stock overvalued right now?
Based on GuruFocus' analysis, Sihuan Pharmaceutical Holdings Group (HKSE:00460) is currently considered Possible Value Trap. The stock's GF Value™ is HK$1.25, compared to a current price of HK$0.79 — trading 37.2% below its estimated fair value. The current Ending Cash Position is HK$3,933 Mil. Sihuan Pharmaceutical Holdings Group's overall GF Score™ is 79/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Sihuan Pharmaceutical Holdings Group (HKSE:00460), the current Ending Cash Position is HK$3,933 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sihuan Pharmaceutical Holdings Group (HKSE:00460) Overvalued in 2026?
Based on GuruFocus' analysis, Sihuan Pharmaceutical Holdings Group stock appears to be undervalued.
The current stock price of HK$0.79 is trading 37.2% below its estimated GF Value™ of HK$1.25.
GuruFocus considers Sihuan Pharmaceutical Holdings Group to be Possible Value Trap.
Key valuation signals for HKSE:00460:
Ending Cash Position: HK$3,933 Mil
GF Value™: HK$1.25 vs. price of HK$0.79 (37.2% below fair value)
No single metric tells the full story. See the HKSE:00460 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sihuan Pharmaceutical Holdings Group Ltd is an investment holding company. Along with its subsidiaries, the company is engaged in the research & development and the manufacture & sale of pharmaceutical products. Its portfolio comprises products for diseases related to the cardio-cerebral vascular (CCV) system, Respiratory, Neurology, and others. The group has three reportable segments: the medical aesthetic products segment, including the filling, shaping, supporting, supplementing, optoelectronic device, body sculpturing, skincare, and others; the innovative medicine and other medicine segment; and the generic medicine segment, which generates key revenue. Geographically, the company generates a majority of its revenue from Mainland China and the rest from the United States.
79GF Score
Get the complete analysis for HKSE:00460
Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:00460 has been successfully added to your 
